News und Analysen
![Humana Announces Support for Louisville to Help Rebuild and Unite City](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Humana Announces Support for Louisville to Help Rebuild and Unite City
Today, Humana (NYSE: HUM) announced actions to support its hometown of Louisville in its efforts to address racial inequity and unite toward a stronger community.
“We are at a pivotal moment in
![Life Sciences Accelerates Use of Remote Meetings to Connect with Healthcare Professionals](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Life Sciences Accelerates Use of Remote Meetings to Connect with Healthcare Professionals
Leveraging digital channels to connect with healthcare professionals (HCPs) is a top priority across the life sciences industry. To accelerate the move toward digital engagement, increasing numbers
![Aurinia Announces Results of Annual General Meeting](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the nine incumbent directors of the Company were elected at the Company’s annual
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study
![Recordati Rare Diseases meldet europäischen Marktauftritt von Isturisa® (Osilodrostat)](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Recordati Rare Diseases meldet europäischen Marktauftritt von Isturisa® (Osilodrostat)
Recordati Rare Diseases meldete heute die Ausbietung von Isturisa® (Osilodrostat). Gemäß einer von der französischen Nationalen Arzneimittelagentur (ANSM) erteilten vorläufigen
![Digirad Celebrates the 20th Anniversary of the First Commercially Performed Solid-state Nuclear Medicine Scan](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Digirad Celebrates the 20th Anniversary of the First Commercially Performed Solid-state Nuclear Medicine Scan
Digirad, a leading provider of nuclear imaging and diagnostic expertise, is celebrating the 20th anniversary of the first commercially performed solid-state nuclear medicine image being scanned
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 41st Annual
![Hanger Announces Findings of Newly Published Study That Reveals Significant Cost Benefits Associated With Earlier Prosthetic Fitting Post-Amputation](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Hanger Announces Findings of Newly Published Study That Reveals Significant Cost Benefits Associated With Earlier Prosthetic Fitting Post-Amputation
Hanger, Inc. (NYSE: HNGR) today announced results of its IMPACT study, which evaluates the impact of overall healthcare costs associated with the timing of definitive fitting and delivery of a
![HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
HemaCare Corporation, a Charles River Laboratories International, Inc. (NYSE:CRL) company and global leader and trusted brand in the customization of human-derived biological products and services
![Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by
![Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Investment Group Ltd](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Investment Group Ltd
Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical stage biopharmaceutical company, today announced that it has entered into a Subscription Agreement, with Apeiron
![Pfizer Establishes New Program to Support Continued Biotechnology Innovation](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Establishes New Program to Support Continued Biotechnology Innovation
Pfizer Inc. (NYSE: PFE) today announced the establishment of the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help
![Albireo Pharma: Jubiläumstipp immer höher – wann fliegt die Decke weg?](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Albireo Pharma: Jubiläumstipp immer höher – wann fliegt die Decke weg?
Zu unserem zehnjährigen Jubiläum stellten wir Dir Albireo Pharma (WKN: A2DF99) als Gratis-Rakete mit einem Chance-Risiko-Verhältnis vor, wie es sonst nur in unserem exklusiven No Brainer Club (NBC)
![Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)
Recordati Rare Diseases announced today the commercial availability of Isturisa® (osilodrostat). Over 50 patients with Cushing’s syndrome have already been initiated on Isturisa® under temporary
![Neueste NBC-Empfehlungen knallen +94% und +41% in wenigen Wochen](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Neueste NBC-Empfehlungen knallen +94% und +41% in wenigen Wochen
Kaum ist der neue Monat angebrochen, knallt es wieder in den NBC-Depots und die Cashberge der Mitglieder erreichen neue Allzeithochs: Mit MEI Pharma (WKN: A1KATX) und Pfenex (WKN: A118RA) schießen
![Hanger to Present at Jefferies Virtual Healthcare Conference](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Hanger to Present at Jefferies Virtual Healthcare Conference
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate in presentations
![Agilent Technologies Announces Pricing of $500 Million of Senior Notes](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Agilent Technologies Announces Pricing of $500 Million of Senior Notes
Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $500 million. The
![Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat
![LivaNova to Present at the Jefferies Virtual Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
LivaNova to Present at the Jefferies Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on
![Agilent Technologies Announces Proposed Offering of Senior Notes](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Agilent Technologies Announces Proposed Offering of Senior Notes
Agilent Technologies Inc. (NYSE:A) today announced it is offering, subject to market and other conditions, a series of senior notes under an automatic shelf registration statement on file with the
![Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results
![Charles River Laboratories to Participate in Jefferies and William Blair Conferences](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, at 10:00 a.m. ET, and
![Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot
Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system
![Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain -
- ATB-346 is more potent than expected; lowest effective dose still to be established -
- Antibe plans